BioNTech SE - ADR vs NRG Energy Inc — how do they compare? BioNTech SE - ADR trades at $89.89 (market cap $22.86B), while NRG Energy Inc trades at $138.77 (market cap $29.19B). The key difference: NRG Energy Inc is the larger of the two by market cap, and NRG Energy Inc pays a 1.37% dividend while BioNTech SE - ADR pays none. Which is the better fit depends on your goals.
| BNTX | NRG | |
|---|---|---|
Market Cap | $22.86B | $29.19B |
Sector | Health | Utilities |
52-Week High | $119.34 | $184.03 |
52-Week Low | $83.89 | $120.65 |
Enterprise Value | $6.53B | $53.02B |
Dividend Yield | — | 1.37% |
Signals from Pluang's Aura AI — not financial advice
BioNTech (BNTX) trades at $90.07, down 1.55% today, amid a bearish technical signal and declining revenue trends. The company reported a net loss of $1.14 billion in 2025, with profitability metrics negative, though it maintains a strong cash position of $16.78 billion. Recent news highlights restructuring efforts, including site closures and a $1 billion share buyback, as it pivots focus to oncology pipeline development following reduced COVID-19 vaccine demand.
The outlook remains challenging with persistent losses and competitive pressures, but analyst consensus is bullish with a $129.67 price target. Key risks include execution of the oncology strategy and revenue volatility. The stock's current valuation reflects uncertainty, offering potential upside if pipeline milestones are met, but investors face significant operational and market headwinds.
NRG Energy trades at $139.48, down 0.67% on the day, with a bearish technical signal despite recent earnings beats. The stock shows mixed fundamentals with a high P/E of 153.27 but attractive P/S of 0.86, while revenue grew to $30.71B in 2025. Analyst sentiment remains positive with 64% buy ratings, though technical indicators suggest near-term pressure with support at $138.
Outlook is cautiously optimistic given strong analyst support and dividend payments, but risks include high debt levels and volatile cash flows. Investors should weigh solid revenue growth against margin compression and elevated valuation multiples before positioning.
Trailing returns across standard periods
Latest headlines on both assets
BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including COVID-19. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies.
Read more on BNTX →NRG Energy is one of the largest retail energy providers in the U.S., with 7 million customers, including its 2021 acquisition of Direct Energy. It also is one of the largest U.S. independent power producers, with 16 gigawatts of nuclear, coal, gas, and oil power generation capacity primarily in Texas. Since 2018, NRG has divested its 47% stake in NRG Yield, among other renewable energy and conventional generation investments. NRG exited Chapter 11 bankruptcy as a stand-alone entity in December 2003.
Read more on NRG →